Providers’ Use of Pharmacogenetic Testing to Inform Antidepressant Prescribing: Results of Qualitative Interviews

Dr. Wray has received support from the VA Center for Integrated Healthcare and the VA Western New York Healthcare System, Buffalo. Dr. Thase has served as an adviser or consultant for Acadia, Akili, Alkermes, Allergan (Forest, Naurex), Axsome, Boehringer-Ingelheim, Clexio Biosciences, GH Therapeutics, H. Lundbeck A/S, Janssen Pharmaceuticals (Johnson and Johnson), Jazz Pharmaceuticals, Otsuka Pharmaceuticals, Perception Neuroscience, Pfizer, Sage Therapeutics, Seelos Pharmaceuticals, Sunovion, and Takeda; he has received grant support from AbbVie, Acadia, Allergan (Forest, Naurex), Alkermes, Assurex Health (now Myriad), Axsome Therapeutics, Clexio, Intracellular, Janssen Pharmaceuticals (Johnson and Johnson), NIMH, Otsuka, the Patient-Centered Outcomes Research Institute, and Takeda; and he receives royalties from the American Psychiatric Association, Guilford Press, Herald House, and W.W. Norton. His spouse is employed by Peloton Advantage and is a senior vice president of Open Health; both of these companies conduct business with pharmaceutical companies. Dr. Oslin has received research support from Johnson and Johnson and Myriad Genetics. The other authors report no financial relationships with commercial interests.